Alimera Sciences Profile

0.87
USD 0.01  1.25%
89%
17%

Acquisition by Szela Mary T of 40000 shares of Alimera Sciences subject to Rule 16b-3

Alimera Sciences insider trading alert for grant of employee stock option (right to buy) by Mary Szela, the corporate stakeholder, on June 21, 2018. This event was filed by Alimera Sciences Inc with SEC on 2018-06-21. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Alimera Sciences Summary

Alimera Sciences (ALIM) is traded on NASDAQ General Markets in USA. It is located in GEORGIA, U.S.A and employs 118 people. Alimera Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 61.63 M. Alimera Sciences conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 70.04 M outstanding shares of which 730.97 K shares are presently shorted by private and institutional investors with about 3.03 trading days to cover. Alimera Sciences currently holds about 20.25 M in cash with (13.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Check Alimera Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 0.869HorizonTargetOdds Above 0.869
88.37%30 days 0.87 11.51%
Based on normal probability distribution, the odds of Alimera Sciences to move above current price in 30 days from now is about 11.51% (This Alimera Sciences probability density function shows the probability of Alimera Sciences Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Armistice Capital Llc 0Common Shares6.9 M7.1 M
Venbio Select Advisor LlcCommon Shares6.2 M6.4 M
View Alimera Sciences Diagnostics

Selected Alimera Sciences Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Alimera Sciences Against Markets

Risk Adjusted
Performance Score (0 to 100)
13 
Chance of
Financial Distress (0 to 100%)
76 
Equity ratings for Alimera Sciences are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences operates under Drug Manufacturers - Major classification in USA and traded on NASDAQ General Markets. It employs 118 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameAlimera Sciences
President CEO, DirectorDaniel MyersView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationGEORGIA, U.S.A
Business Address6120 Windward Parkway
ExchangeNASDAQ General Markets
CIK Number01267602.0
CUSIP016259103
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.alimerasciences.com
Contact Number678 990 5740
CurrencyUSD - US Dollar

Recommendations

Alimera Sciences Analyst Recommendations
Target PriceAdvice# of Analysts
3.0Strong Buy1Odds
Alimera Sciences current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Alimera Sciences Analyst Advice  

Earnings

Alimera Sciences Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.05March 1, 2017
Alimera Sciences normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Alimera Sciences Corporate Directors
James Largent Independent Director, MBA
Peter Pizzo Independent Director, Ph.D
Calvin Roberts Independent Director, Ph.D
Check also Trending Equities. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.